Clinical Trials Logo

Clinical Trial Summary

This is a single-arm, open, Phase II clinical study of Tislelizumab combined with lenvatinib and Gemox regimen for transformational treatment of potentially resectable locally advanced malignant tumors of biliary system.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT05036798
Study type Interventional
Source Tianjin Medical University Cancer Institute and Hospital
Status Not yet recruiting
Phase Phase 2
Start date September 17, 2021
Completion date January 30, 2023